GAMMA Investing LLC Acquires 1,585 Shares of XOMA Royalty Corporation (NASDAQ:XOMA)

GAMMA Investing LLC raised its holdings in XOMA Royalty Corporation (NASDAQ:XOMAFree Report) by 1,063.8% in the first quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The firm owned 1,734 shares of the biotechnology company’s stock after purchasing an additional 1,585 shares during the period. GAMMA Investing LLC’s holdings in XOMA Royalty were worth $35,000 at the end of the most recent quarter.

A number of other institutional investors have also recently bought and sold shares of XOMA. Woodline Partners LP lifted its holdings in shares of XOMA Royalty by 63.9% during the 4th quarter. Woodline Partners LP now owns 156,266 shares of the biotechnology company’s stock worth $4,107,000 after acquiring an additional 60,927 shares during the period. Eversept Partners LP lifted its holdings in shares of XOMA Royalty by 1.2% during the 4th quarter. Eversept Partners LP now owns 95,417 shares of the biotechnology company’s stock worth $2,508,000 after acquiring an additional 1,128 shares during the period. Northern Trust Corp lifted its holdings in shares of XOMA Royalty by 1.5% during the 4th quarter. Northern Trust Corp now owns 91,181 shares of the biotechnology company’s stock worth $2,396,000 after acquiring an additional 1,340 shares during the period. Charles Schwab Investment Management Inc. lifted its holdings in shares of XOMA Royalty by 5.8% during the 4th quarter. Charles Schwab Investment Management Inc. now owns 23,113 shares of the biotechnology company’s stock worth $607,000 after acquiring an additional 1,276 shares during the period. Finally, Renaissance Technologies LLC lifted its holdings in shares of XOMA Royalty by 89.8% during the 4th quarter. Renaissance Technologies LLC now owns 16,100 shares of the biotechnology company’s stock worth $423,000 after acquiring an additional 7,619 shares during the period. Institutional investors own 95.92% of the company’s stock.

Analyst Ratings Changes

A number of brokerages have recently weighed in on XOMA. Wall Street Zen raised shares of XOMA Royalty from a “hold” rating to a “buy” rating in a report on Saturday, June 14th. Benchmark began coverage on shares of XOMA Royalty in a report on Thursday, April 17th. They set a “buy” rating and a $35.00 price target for the company. Finally, HC Wainwright reissued a “buy” rating and issued a $104.00 price objective on shares of XOMA Royalty in a research note on Wednesday, May 28th.

Read Our Latest Stock Analysis on XOMA Royalty

Insider Buying and Selling at XOMA Royalty

In other XOMA Royalty news, Director Joseph M. Limber purchased 17,935 shares of the company’s stock in a transaction dated Thursday, April 3rd. The stock was purchased at an average price of $25.24 per share, with a total value of $452,679.40. Following the completion of the purchase, the director now owns 16,524 shares of the company’s stock, valued at approximately $417,065.76. The trade was a -1,271.08% increase in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at this link. Also, major shareholder Bvf Partners L. P/Il sold 392,723 shares of the firm’s stock in a transaction on Friday, May 16th. The shares were sold at an average price of $27.10, for a total transaction of $10,642,793.30. Following the transaction, the insider now directly owns 1,267,545 shares of the company’s stock, valued at $34,350,469.50. The trade was a 23.65% decrease in their position. The disclosure for this sale can be found here. Insiders have purchased 25,178 shares of company stock worth $636,300 over the last quarter. Corporate insiders own 9.10% of the company’s stock.

XOMA Royalty Stock Performance

Shares of XOMA Royalty stock opened at $27.32 on Friday. XOMA Royalty Corporation has a fifty-two week low of $18.35 and a fifty-two week high of $35.00. The company has a debt-to-equity ratio of 1.18, a current ratio of 5.54 and a quick ratio of 5.54. The firm has a market capitalization of $327.02 million, a P/E ratio of -23.76 and a beta of 0.94. The company’s 50 day moving average price is $24.88 and its two-hundred day moving average price is $24.31.

XOMA Royalty (NASDAQ:XOMAGet Free Report) last issued its earnings results on Tuesday, May 13th. The biotechnology company reported $0.06 earnings per share for the quarter, beating analysts’ consensus estimates of ($0.26) by $0.32. XOMA Royalty had a negative net margin of 13.04% and a negative return on equity of 12.43%. The firm had revenue of $15.91 million for the quarter, compared to analyst estimates of $6.75 million. On average, equities analysts forecast that XOMA Royalty Corporation will post -1.41 earnings per share for the current fiscal year.

XOMA Royalty Company Profile

(Free Report)

XOMA Corporation operates as a biotech royalty aggregator in the United States and the Asia Pacific. It has a portfolio of economic rights to future potential milestone and royalty payments associated with partnered commercial and pre-commercial therapeutic candidates. The company also focuses on early to mid-stage clinical assets primarily in Phase 1 and 2 with commercial sales potential that are licensed to partners; and acquires milestone and royalty revenue streams on late-stage clinical or commercial assets.

Read More

Want to see what other hedge funds are holding XOMA? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for XOMA Royalty Corporation (NASDAQ:XOMAFree Report).

Institutional Ownership by Quarter for XOMA Royalty (NASDAQ:XOMA)

Receive News & Ratings for XOMA Royalty Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for XOMA Royalty and related companies with MarketBeat.com's FREE daily email newsletter.